India’s Production-Linked Scheme Will Enhance Domestic Bulk Drug Manufacturing Capabilities
Key View
- India’s production-linked incentive scheme will reduce imports by promoting domestic manufacturing of pharmaceuticals.
- The country will remain keen to secure its drugs market from external shocks, lessen import dependencies, and continue support for the domestic production capabilities in APIs.
- Reducing India’s dependence on Mainland China will not be easy to achieve.
India’s production-linked incentive (PLI) scheme will reduce import by promoting domestic manufacturing of pharmaceuticals. The Indian government approved a production-linked incentive (PLI) scheme in February 2021 targeting India’s pharmaceutical sector for enhancing drug manufacturing capabilities and expanding exports. The key objectives of the scheme are:
Related Posts
Thai economic growth forecast revised up to 3.2% in 2022 (EIC)
EIC revised up the Thai economic growth forecast to 3.2% (from the previous 3.0%) in 2022. An upward revision...
Thai exports edged up amid signs of global economic slowdown
The value of Thai merchandise export in September accelerated from the previous month.The value of Thai merchandise exports in...
The Thai economy continued to recover following better domestic demand
The Thai economy continued to improve in Q2/22.The Thai economy continued to expand for the third consecutive quarter by...
